Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

• Status: Completed
• Trial end date: 2021-01-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if the use of inhaled beclomethasone after a community-acquired respiratory viral infection in a lung transplant recipient decreases the risk of the subsequent development of chronic lung allograft dysfunction.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Treatments: Beclomethasone

Criteria

Inclusion Criteria:

• Adult (≥ 18 years old)

• Single, bilateral, or heart-lung transplant recipient

• Confirmed infection with a community-acquired respiratory virus including: adenovirus, coronavirus, influenza A or B, respiratory syncytial virus (RSV), parainfluenza virus (PiV), human metapneumovirus (hMPV), and rhinovirus

• At least 6 months post-transplant, with completion of 6 month bronchoscopy if indicated

• Able and willing to give written informed consent and comply with study procedures (e.g. testing, treatment)

Exclusion Criteria:

• BOS Stage 3

• Requirement for mechanical ventilation at study entry

• Use of inhaled steroids at the time of CARV infection

• Any condition that in the investigator's opinion would preclude the patient's participation in a clinical trial

• Lack of available spirometric data to establish a baseline forced expiratory volume in 1 second and/or forced vital capacity

• Pregnancy

• Current participation in another interventional clinical trial